Urology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Pathology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
BMJ Case Rep. 2021 Aug 17;14(8):e240613. doi: 10.1136/bcr-2020-240613.
Neuroendocrine tumours (NETs) of the urinary tract are rare, and the urinary bladder is the the most common primary site. Primary ureteric NET is rarer with under 80 cases reported in the literature thus far. Most of these tumours are of the high-grade small cell neuroendocrine carcinoma subtype, which has a worse prognosis. Neoadjuvant chemotherapy has a proven role in the management of NET of the bladder as it downstages the tumour, which may add to significant recurrence-free survival and overall survival. We report the successful management of a patient with locally advanced small cell neuroendocrine carcinoma of the ureter, who had a pathological complete response after neoadjuvant chemotherapy with etoposide and cisplatin. He subsequently received adjuvant chemotherapy followed by radiation and is recurrence-free at a follow-up of 1 year.
泌尿系统神经内分泌肿瘤（NET）较为罕见，其中膀胱是最常见的原发部位。而原发输尿管 NET 则更为罕见，目前文献报道不足 80 例。这些肿瘤大多数为高级别小细胞神经内分泌癌亚型，预后更差。新辅助化疗在膀胱 NET 的治疗中已被证实具有作用，因为它可以使肿瘤降期，从而可能显著增加无复发生存率和总生存率。我们报告了一名局部晚期输尿管小细胞神经内分泌癌患者的成功治疗，他在接受依托泊苷和顺铂新辅助化疗后获得了病理完全缓解。随后他接受了辅助化疗、放疗，随访 1 年无复发。
